比伐卢定作为肝素替代方案在颈动脉支架术中的安全性与有效性
基于血管质量倡议(VQI)注册数据库2010至2022年颈动脉支架术数据,经倾向性匹配比较肝素与比伐卢定两组各957例患者,发现术后神经事件、出血、30天及1年死亡率均无显著差异,提示比伐卢定可作为肝素禁忌患者的替代抗凝选择。
要点
- 在80,172例颈动脉支架术中,2,789例(3.47%)使用比伐卢定。
- 倾向性匹配后两组各957例,神经事件OR 1.44(95%CI 0.72-2.86;P=0.30)无显著差异。
- 出血、30天死亡及1年死亡风险在两组间均无显著差异。
核心结论
- 比伐卢定是肝素禁忌患者接受颈动脉支架术时安全有效的肝素替代方案。
- 研究结果显示两组结局无显著差异,支持比伐卢定作为可行的抗凝选择。
研究设计与样本
- 回顾性队列研究,查询血管质量倡议(VQI)注册数据库2010至2022年颈动脉支架术病例。
- 共纳入80,172例颈动脉支架术,其中2,789例(3.47%)使用比伐卢定。
- 采用倾向性匹配分析比较肝素组与比伐卢定组结局,匹配后每组957例。
主要发现
- 肝素组中24,797例(34.1%)行经股动脉颈动脉支架术(TFCAS)联合远端栓塞保护,47,961例(65.9%)行经颈动脉血运重建术(TCAR)联合血流逆转。
- 比伐卢定组中2,494例(91.2%)行TFCAS,240例(8.8%)行TCAR。
- 神经事件(卒中或短暂性脑缺血发作)风险比伐卢定组 vs 肝素组 OR 1.44(95%CI 0.72-2.86;P=0.30),无显著差异。
- 出血风险比伐卢定组 vs 肝素组 OR 1.0(95%CI 0.53-1.90;P=1.00),无显著差异。
- 30天死亡率比伐卢定组 vs 肝素组 OR 2.05(95%CI 0.62-6.85;P=0.24),1年死亡率 OR 1.37(95%CI 0.84-2.24;P=0.21),均无显著差异。
临床怎么用
- 对于有肝素禁忌的颈动脉支架术患者,比伐卢定可作为肝素替代抗凝方案。
- 使用比伐卢定时术后神经事件、出血及死亡风险与肝素无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transfemoral carotid artery stenting (TFCAS) and transcarotid artery revascularization (TCAR) are commonly used to treat carotid stenosis. However, the need for heparin alternatives during these procedures and their impact on outcomes remain unclear. This study evaluates the safety and efficacy of bivalirudin, the most commonly used heparin alternative, compared to heparin. METHODS: The Vascular Quality Initiative registry was queried for carotid artery stenting procedures performed from 2010 to 2022. Propensity-matched analyses compared outcomes between patients receiving intraprocedural heparin and those receiving bivalirudin. Primary outcomes were postoperative neurological events, including stroke or transient ischemic attack, and bleeding. Secondary outcomes included 30-day rates of reintervention and myocardial infarction, and mortality at 30 days and 1 year. RESULTS: Among 80,172 carotid artery stenting procedures, 2,789 (3.47%) were performed with bivalirudin. In the heparin group, 24,797 (34.1%) underwent TFCAS with distal embolic protection, while 47,961 (65.9%) underwent TCAR with flow reversal. In the bivalirudin group, 2,494 (91.2%) underwent TFCAS, and 240 (8.8%) underwent TCAR. Propensity matching created 2 cohorts of 957 patients each. There were no significant differences in neurological events (odds ratio, [OR]: 1.44, 95% confidence interval [CI]: 0.72-2.86; P = 0.30), bleeding (OR: 1.0, 95% CI: 0.53-1.90; P = 1.00), 30-day mortality (OR: 2.05, 95% CI: 0.62-6.85; P = 0.24), or 1-year mortality (OR: 1.37, 95% CI: 0.84-2.24; P = 0.21). CONCLUSION: Bivalirudin is a safe and effective alternative to heparin for patients with contraindications to heparin undergoing carotid artery stenting. These findings suggest no significant differences in outcomes, supporting bivalirudin as a viable anticoagulation option.
引用
- Kania TA, Shah S, Guo T, et al. Safety and Efficacy of Bivalirudin as a Heparin Alternative in Patients Undergoing Carotid Artery Stenting. Ann Vasc Surg. 2025. PMID: 40447033. doi:10.1016/j.avsg.2025.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。